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Background: To study the response of standard 
interferon and ribavirin  in patients with chronic 
hepatitis  C. 
Methods: In this descriptive study 235 adult 
patients of hepatitis C infection who received  3 MIU 
interferon three times a week along with Ribavirin 
1000-1200 mg/day,for  a period of 24 weeks, were 
enrolled . End of Treatment Response (ETR) was 
assessed by testing HCV RNA by PCR. The efficacy 
of the treatment was evaluated by Sustained 
Virological Response (SVR) and those with 
detectable HCV RNA were labeled as relapsers.  
Results: Majority (76.74%) showed  SVR 
undetectable HCV RNA. Out of them 78.89% were 
females. Relapse was encountered in 23.26% 
patients. 
Conclusion: Conventional Interferon in addition 
with Ribavirin administration is effective in 
majority of patients  
  
Introduction 
      Hepatitis C virus (HCV) belongs to the family of 
Flaviviridae and is a single-stranded RNA virus. 
Approximately 170 million people are infected with 
hepatitis C virus world wide. Those infected by HCV 
are expected to develop chronic hepatitis in 80% of 
whom 25% to 30% develop liver cirrhosis. HCV is a 
major etiological factor for the development of 
hepatocellular carcinoma (HCC) and annual risk of 
developing HCC is 1-4% per year5. HCV attributes to 
over 280,000 deaths out of 1.4 million deaths caused by 
chronic liver disease only in year 2002. 1-5 
     More than 10 million individuals in Pakistan are 
infected with HCV. Genotype 2 and 3 are more 
common and Genotype-1 is rare6.  Hepatitis C is 
passed through contact with contaminated blood. 
Most of the cases of HCV infection remain 
asymptomatic or have only a few nonspecific 
symptoms including malaise, nausea, anorexia, 
weakness, myalagia and arthralgia. Jaundice is present 
in less than 25% cases. Spontaneous resolution of acute 
HCV infection is also less frequent as compared to 
Hepatitis B virus infection. Only 15-20% cases of acute 
HCV infection resolve spontaneously. Those who 
develop CLD if untreated usually develop 
decompensated liver disease with development of 
ascites, esophageal varices and other sinister sequelae. 
Five year survival in patients with decompensated 
CLD is 50%. 6-8  
       Pegylated Interferon (Peg IFN) plus Ribavirin 
(Rib) is  considered as the most effective treatment for 
chronic HCV infection. Nonetheless treatment with 
standard Interferon (IFN) plus Ribavirin has also been 
significantly useful.9 Even so treatment with Peg IFN is 
3-4 times costly, comparing cost of treatment with 
standard IFN plus Ribavirin9. 
      Sustained Virological Response (SVR) with Peg 
IFN plus Rib in HCV: Genotype 2 and 3 patients are 
around 90% whereas SVR with standard IFN+Rib in 
similar population treated for the similar duration is 
around 76%. Unfortunately cost of initial diagnostic 
workup in addition to explicit antiviral treatment is 
high and remains impractical for many 
underprivileged patients.10  National program for 
prevention and control of Hepatitis provided an 
opportunity to a large number of patients with chronic 
HCV infection to get gratis treatment since last 
decade.11 The program provided added opportunity to 
evaluate various aspects of HCV disease in patients 
reporting to medical facilities.  
 
Patients and Method 
      A total number of 235 adult patients were included 
in the study conducted at the department of Internal 
Medicine of DHQ Teaching Hospital Mirpur AJ&K 
from July 2009 to July 2011.  Out of the total number 66 
were males and 169 were females ranging from 20 to 
60 years of age. Quantitative test for HCV RNA by 
PCR and Genotype were done in all patients.  Those 
above the age of 60 years, having de-compensated 
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liver disease, chronic renal failure, significant 
cardiovascular disease, active thyroid disease, severe 
depression, hemoglobin less than 10 grams/dl, and 
platelet count less than 100000/c mm were excluded 
from the study.  
    All the patients were counseled for the need, 
duration and possible side effects of the treatment. 
Standard Interferon 3 MIU three times a week was 
administered and Ribavirin 1000-1200 mg/day, in 
divided doses depending upon body weight was 
prescribed. Drugs were provided to all patients on 
monthly basis. All patients were called after every 02 
weeks for follow up covering initial 6-8 weeks of 
treatment. Total period of treatment spread on 24 
weeks. End of Treatment Response (ETR) was assessed 
by testing HCV RNA by PCR. Responders with 
undetectable HCV RNA were advised to get HCV 
RNA test done after six months of conclusion of 
treatment to evaluate Sustained Virological Response 
(SVR). Those with detectable HCV RNA were labeled 
as relapsers.  
Results 
      Out of the total 235 patients enrolled in this study, 
28.09% were males and 71.92% were females. Mean 
age of the patients was 38.6 years (ranging from 20 to 
60 years).Out of the total, 186 patients (79.14%) 
completed treatment with end of treatment response 
(ETR) report. At the end of treatment 141 patients 
(75.80%) responded with undetectable HCV RNA 
while 45 (24.19%) were non-responders. Male 
responders were 40 (78.40%) and nonresponders male 
were 11(21.56%). Female responders were 101 
(74.80%) and female nonresponders were 34(25.18%) 
(Table 1). Out of 141 responders only 129 patients 
turned up after six months with SVR report. Out of 
those 99 patients (76.74%) attained SVR with 
undetectable HCV RNA. Out of them 28 (71.79%) were 
males and 71 (78.89%) were females . We encountered 
relapse in 30 (23.26%) patients. Out of those 11 (28.21% 
were males and 19 (21.11%) were females (table 2). 
 
Table1: Standard Interferon and Ribavirin 
Therapy: End of Treatment Response 






186 (100) 141(75.80) 45(24.19) 
Males 51(27.40) 40(78.40) 11(21.56) 
Females 135(72.58) 101(74.80) 34(25.18) 
Table 2: Standard Interferon and Ribavirin 
Therapy: Sustained  Viral Response analysis 





 No of Patients 129 (100) 99 (76.74) 30 (23.26) 
Males 39 (30.23) 28(71.79) 11(28.21) 
Females 90 (69.77) 71(78.89) 19 (21.11) 
   
Discussion: 
     Prevalence of patients with Hepatitis C is high 
worldwide and speedily increasing in Pakistan. 
Mandatory screening of blood donors and increasing 
trend of screening the patients before surgical and 
dental procedures is playing  an important role in 
unearthing new cases of HCV.12  ( Genotype 3 was 
dominant in present series). In present series 27.40% 
were males and 72.58% were females. This is an 
unusual finding compared with the previous studies 
which show a male predominance of HCV infection. 
Over all ETR was good and almost similar to the 
earlier studies in different regions of Pakistan.  
Sustainable ETR was found in 141 patients (75.80%) 
with undetectable HCV RNA by PCR. Out of 51 males 
who completed treatment responders were 78.40%. 
Out of 135 females who completed treatment 101 
(74.80%) responded and 34 (25.18%) failed to respond. 
Adherence to treatment was almost similar in both 
males and females. In this study ETR is better in males 
than in females; however some previous studies had 
shown better response in females13. Counseling for the 
importance and need of SVR test attained was done 
with all patients who had attained ETR. Out of 141 
patients who attained ETR, 70.49% came back with 
SVR report after six months of completion of 
treatment.  Viral clearance with undetected RNA was 
found in 76.74% patients and 23.26% patients had 
relapsed. SVR in our series is similar to the previous 
results14. Males who attained SVR were 71.79% and 
28.21% relapsed. Females who attained SVR were 
78.89% and 21.11% relapsed. This confirms females 
having better sustainable response to treatment.    In 
one of the Meta analysis it was demonstrated that of 
16n trials where PEG INF plus RBV were compared 
with INF plus RBV, the efficacy of the INF+RBV was 
considerable though slightly lower than PEINF+RBV 
but still SVR is acceptable choice for the treatment of 
chronic Hepatitis C in Genotype 2 and 3 virus15. The 
impact of dose of RBV has been also determined 
through clinical trials and it was found that although 
there was favorable effect on the higher compared to 
the lower dose of RBV on SVR in HCV-G4, this effect 
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did not reach statistical significance. The difference in 
the rate of SVR attained by PEG IFN-a-2a and -a-2b 
has been a subject of intense debate. In one prospective 
non-randomized, open-label study, comparison was 
made of naive HCV-infected patients treated with PEG 
IFN-a-2a plus RBV or PEG IFN-a-2b plus RBV; SVR 
was similar in both groups (65.9% vs 62%, P = 0.64), 
without differences according to genotype16. Though 
there are other trials reporting higher SVR rates with 
PEG IFN-a-2a compared with PEG IFN-a-2b. In one 
prospective, randomized, Italian study more patients 
treated with PEG IFN-a-2a plus RBV significantly 
achieved SVR compared with those treated with PEG 
IFN-a-2b plus RBV (68.8% vs 54.4%, respectively; p = 
0.008).17 The results of these and similar studies 
suggest that therapy with PEG IFN combined with 
RBV compared with Standard INF plus RBV shows 
definite improvement in sustainable virus response 
(SVR).18 Treatment cost is much higher when treated 
with PEG-INF is much higher than when treated with 
standard INF.19,20   
 
Conclusion 
1.Conventional Interferon plus Ribavirin therapy in 
patients with Genotype 2 and 3 is useful and a cost 
effective choice.  
2. Retreatment with pegylated Interferon plus 
Ribavirin is a probable option in non-responders. 
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